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was better than in those without pre-existing disease (Hollander et 
al). The implication is that the OA knee (at least in post-traumatic 
disease) is a good environment in which to implant a maturing 
tissue. At the very least these surprising data should remind us to 
keep an open mind as to the chances of successfully regenerating 
cartilage, even in patients with quite advanced disease.
In order to move to a point where we can maximise our chances 
of implanting mature cartilage engineered from chondrocytes or 
TUFNDFMMTXFOFFEUPIBWFTPNFDPO¾EFODFUIBUXFDBODSFBUFB
tissue that will have some mechanical stability and that will behave 
CJPMPHJDBMMZ JO B XBZ UIBU NBYJNJTFT UIF DIBODF UP JO¿VFODF UIF
disease process. In order to resurface large areas of denuded bone 
within an OA knee it will be necessary to create large sheets of 
cartilage and to ensure that it is as close to the articular cartilage 
QIFOPUZQF BT QPTTJCMF 'VSUIFSNPSF JU XJMM CF FTTFOUJBM UP ¾OE B
method of integrating this cartilage with surrounding natural tissues 
(cartilage and bone). We have made advances on both these fronts. 
Whilst some studies have suggested that OA bone marrow stem 
DFMMT BSF EF¾DJFOU JO UIFJS DIPOESPHFOJD DBQBDJUZ XF IBWF GPVOE
that in fact, given appropriate growth factor cues delivered at the 
right times, it is possible to engineer cartilage from these cells that 
is as good as anything that can be created using the best source 
of chondrocytes. Furthermore we can down-regulate the tendency 
of chondrocytes generated from stem cells to differentiate down 
the hypertrophic phenotype. With respect to integration, it seems 
probable that implantation of a mature cartilage will require co-
implantation of cells that can actively unite the implant and host 
tissues. We are attempting to achieve this using a “cell bandage” 
technology that could be used for a range of different tissues.
Commercial products are already available that are being implanted 
into large lesions without the use of integrating methodology. 
Hyalograft C (Fidia) and CaRes (Arthrokinetiks) could both potentially 
CF JNQMBOUFE JOUP MBSHF VODPO¾OFE MFTJPOT )PXFWFS UIFTF BSF
immature implants (mostly cells with very little extracellular matrix) 
and it is at present uncertain if they would provide mechanical 
stability early enough or quickly enough to stabilise the OA joint.
It is far too early to know if implantation of engineered cartilage, 
alone or in combination with other surgical interventions, can have 
B TJHOJ¾DBOU JNQBDU PO UIF QSPHSFTTJPO PG 0" *U JT DMFBS UIBU UIF
technology is fast approaching the point where such intervention 
is possible and that methods for implantation and integration will 
be available to us. Biological implants by their very nature are not 
passive and it is not unreasonable to pose the hypothesis that a 
living tissue implant will not just provide a mechanical replacement 
for lost cartilage but could also have a direct positive effect on the 
subchondral bone and surrounding tissues. Until this hypothesis 
has been tested in animal models and in patients we should keep an 
open mind about the place of tissue engineering and cell therapies 
in the treatment of OA.
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8.3
The clinician view 
M. Marcacci, E. Kon, B. Grigolo, M. Delcogliano, G. Filardo, M.P. 
Neri, Italy 
In recent years, several options have become available to treat 
cartilage lesions. Given the intrinsic limitations of these techniques, 
newer surgical approaches have been developed focused on 
obtaining a complete regeneration of the hyaline cartilage as well 
as a complete integration with the surrounding tissues, to restore 
the normal knee function and to provide durable outcomes. 
The cell-based approach, known as Autologous Chondrocyte 
*NQMBOUBUJPO	"$*
XBT¾STU JOUSPEVDFE JO4XFEFO JO5JTTVF
engineering strategy is based on the use of biodegradable polymers 
as temporary scaffolds for the in vitro growth of living cells and 
their subsequent transplantation into the defect site. Hyaluronic 
acid has proven to be an ideal molecule for tissue engineering 
strategies in cartilage repair, given its impressive multi-functional 
activity in cartilage homeostasis. Hyalograft® C Autograft (Fidia 
Advanced Biopolymers, Abano Terme, Italy) is a hyaluronan-based 
scaffold cultured with autologous chondrocytes. Three-dimensional 
nonwoven scaffolds based on HYAFF® 11 support the in vitro growth 
of highly viable chondrocytes and promote the expression of their 
original chondrogenic phenotype.2 Chondrocytes, previously 
expanded on plastic and seeded into the HYAFF® 11 scaffold produce 
a characteristic extracellular matrix rich in proteoglycans and 
express typical markers of hyaline cartilage, such as collagen II and 
aggrecan2,3 Some studies showed that differentiated phenotype 
of chondrocytes grown in monolayers in vitro can be restored 
CZ TFFEJOH UIF DFMMT JO B UISFFEJNFOTJPOBM DPO¾HVSBUJPO UIVT
BMMPXJOH UIF DFMMT UP SFFYQSFTT UIFJS TQFDJ¾D HFOFT TP JUXPVME
be possible to hypothesize a further use of this biomaterial in the 
treatment of early cartilage lesions also in OA patients. HYAFF® 11-
based tissue engineered cartilage implant showed good results in 
focal cartilage lesions,5,6,7,8 but it’s utilize in osteoarthritis was 
purely investigated. The cell-based therapies developed to date for 
cartilage are indicated only for acute cartilage defects; however, the 
more common diseases of articular cartilage, primarily osteoarthritis, 
usually result in more extensive damage, which is currently treated 
with total joint replacements. The possibility to treat early stage 
arthritic lesions with tissue engineered cartilage is very attractive. In 
this review, we will present our clinical experience with Hyalograft® C 
autologous chondrocyte implant on a three-dimensional Hyaluronan-
based matrix also in patients affected by osteoarthritis. 
Implant preparation and implantation The surgical technique for 
Hyalograft C autologous chondrocytes implant consists of two 
TUFQT5IF¾STUQSPDFEVSFDPOTJTUTPGBCJPQTZPGIFBMUIZDBSUJMBHF
for autologous chondrocyte cell culture. This is usually performed 
arthroscopically, when the chondral lesion has been observed, 
and the indication for ACI has been made. A 150–200 mg cartilage 
biopsy is taken from a nonweight bearing site of the articular surface 
(intercondylar notch) and sent to the processing center in a serum-
free nutritional medium. The following day the tissue is minced 
into smaller pieces and digested with 0.25% trypsin at 37_C for 
15 min and then with 300 U/ml collagenase type II (Worthington, 
Lakewood, NJ, USA) at 37 °C for 4 h in Ham’s F12. The digested 
material is centrifuged at 1,000 rpm for 10 min and the pellet is 
resuspended in Ham’s F12 containing 10% fetal calf serum (Sigma), 
1% penicillin–streptomycin, 1% L-glutamine, 1 ng/ml TGFb1, 1 
ng/ml insulin, 1 ng/ml EGF, and 10 ng/ml bFGF (all growth factors 
XFSFSFDPNCJOBOUBOEPGIVNBOTFRVFODF
$FMMTBSFBNQMJ¾FE JO
monolayer cultures up to three passages, then they were seeded 
onto Hyalograft C scaffolds (2x2 cm). 8x106 cells are resuspended in 
0.4 ml of medium (as above, but containing 50 mg/ml ascorbic acid), 
the cell suspension is pipetted onto the scaffold and the culture is 
kept at 37 °C, 5% CO2 overnight. The next day, additional medium 
is added to submerge the cell construct completely, whereas the 
medium is changed twice a week. Hyalograft C chondrocyte cultures 
are ready for shipment after 2 weeks in culture. The day of shipment 
the cell construct is washed exhaustively with PBS then sealed in a 
sterile plastic tray containing 4 ml of nutritional medium. The expiry 
time of the product once packaged is 72 h. The engineered graft was 
implanted at the lesion site by a mini-arthrotomy under regional or 
HFOFSBM BOFTUIFTJB JO B UPVSOJRVFUDPOUSPMMFE CMPPEMFTT ¾FME PS
when indicated, through arthroscopy using a customized instrument 
set.9 Before implantation, the articular cartilage lesion was debrided 
to have healthy cartilage surrounding the defect, taking care to 
minimize excessive bleeding at the site of implantation. Hyalograft®
$XBTDVUJGOFDFTTBSZUP¾UUIFEFGFDUBOEUIFOXBTTJNQMZQMBDFE
into the prepared lesion where in the majority of cases, it was stable 
XJUIPVU UIFOFFE GPS BOZ¾YBUJPONFUIPECFDBVTFPG UIF JOUSJOTJD
adhesive properties of the hyaluronan scaffold.10 Otherwise, in large 
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uncontained defects, particularly in the patellofemoral compartment, 
¾CSJOHMVFBOEPSTVUVSFTXBTFWFOUVBMMZVTFEUPLFFQUIFHSBGUJO
QMBDF"GUFSUPVSOJRVFUSFMFBTFUIFLOFFXBTNPCJMJ[FEUPDPO¾SN
adherence and stability of the graft before standard closure of the 
surgical incision. Patient selection and evaluation 111 consecutive 
patients, treated with autologous chondrocyte Hyalograft C 
implantation in 11 Italian orthopaedic centers, were evaluated at 
mean 4 years follow-up. 75.5% of patients had a single lesion and 
the remaining 24.5% had more than one lesion, corresponding to 
a total number of 235 defects in 192 patients, averaging 1.2 defects 
per patient. The majority of the defects was localized on femoral 
condyles (75.7%), primarily in the medial compartment (81.6%). The 
remainder of the defects was localized on the trochlea (21, 8.9%), 
patella (18, 7.7%), and tibial plateau (18, 7.7%). The defects treated 
were mostly Outerbridge grade IV (86.8%). The mean surface area 
implanted per patient was 3.5 cm2 (standard deviation = 2.7) with 
a maximum value of 19 cm2. 32 patients presented osteoarthritis: 
18 early or mild (Ahlback grade I-II) and 14 severe Ahlback 
grade III-IV) osteoarthritis. Data collection was performed using 
standardized case report forms widely based on those designed 
by the International Cartilage Repair Society (ICRS) evaluation 
package11,12 based on the following scoring systems: International 
Knee Documentation Committee (IKDC) subjective evaluation of knee 
symptoms, function and activity level, and objective knee functional 
test according to the IKDC Knee Examination Form, ICRS knee 4-level 
scale functional status and EuroQol EQ-5D questionnaire for health-
related quality of life assessment. The patients who at the time of 
follow up visit had required a reoperation to remove the implant, re-
implant or a procedure that violated the subchondral bone to treat 
the defect13: were considered as failures and discussed separately. 
Twenty-two patients had consented to the taking of a biopsy for 
investigative purposes from the area of implantation, allowing 
histologic and immunohistochemical assessment of the repair 
tissue. Biopsy specimens were processed for standard histology 
and immunohistochemistry after separation of cartilage from the 
subchondral bone preserving the cartilage-bone interface. Frozen 
sections of cartilage were stained with hematoxylin and eosin (H&E) 
for general histology, Toluidine Blue or Safranin O for proteoglycan 
PCTFSWBUJPO BOE NPOPDMPOBM BOUJCPEJFT TQFDJ¾D GPS 5ZQF * BOE **
collagen. Biopsy sections were analyzed under standard light by 
two independent investigators who were blinded to the treatment 
outcomes and who rated the newly formed cartilage as hyalinelike, 
¾CSPDBSUJMBHF PS NJYFE UJTTVF CBTFE PO DSJUFSJB PG DFMMVMBSJUZ
cell distribution, matrix composition and collagen Type I and II 
immunolocalization.13,14 Statistical analysis The entire set of data 
collected was entered in a single database by an independent contract 
research organization. Statistical analysis was performed using the 
SAS statistical package (SAS Institute, Cary, NC, USA). Baseline data 
were analysed by descriptive statistics. Paired t-test was used to 
compare the preoperative and follow-up status for subjective knee 
evaluation and EQ-VAS. Similarly, the Wilcoxon signed rank test was 
used to compare non-parametric variables such as improvements 
in IKDC objective scores, ICRS knee functional status and EuroQol 
levels. Possible correlations between some lesion characteristics 
and IKDC subjective improvement were analyzed by univariate and 
multivariate analysis (variance analysis ANOVA). A p value <0.05 
XBTDPOTJEFSFEUPCFTUBUJTUJDBMMZTJHOJ¾DBOU
"UBNFBOGPMMPXVQUJNFPGNPOUITBTJHOJ¾DBOUJNQSPWFNFOU	Q
< 0.0001) was observed related to patient’s functional status. There 
XBT B TJHOJ¾DBOU JNQSPWFNFOU JO LOFF GVODUJPO TZNQUPNT BOE
patient’s activity level, with a mean IKDC score which increased from 
39.6 to 72.3 post-operatively. (p<0.0001). One hundred twenty-nine 
patients (91.5%) experienced an improvement with respect to their 
pre-surgery status. Objective functional outcome was evaluated 
by the IKDC scoring system. At the follow-up clinician examination 
95.7% knees of the knees were rated as normal or nearly normal. 
Improvement was not related to the lesion characteristics analyzed, 
UIBU JT EJBHOPTJT TJ[F BOE UZQF PS MPDBUJPO IPXFWFS TJHOJ¾DBOU
improvements (p<0.005) were observed in all of the patients 
subgroups categorized according to these characteristics. The higher 
IKDC scores at follow up (> 82 points in average) were obtained 
by patients with lesions caused by trauma and osteochondritis 
dissecans. Worst clinical outcome was observed in patients (65,6 
points in average) with severe grade of osteoarthritis. The presence 
PGPTUFPBSUISJUJTJTUIFPOMZWBSJBCMFUIBUTJHOJ¾DBOUMZDPSSFMBUFXJUI
the clinical outcome (p=0.0008). Therefore patients reported a 
TJHOJ¾DBOUJNQSPWFNFOUJOBMMTJOHMFDBUFHPSZXFBOBMZ[FECVUCFUUFS
results were for those patients with no symptoms of osteoarthritis. 
Histological analysis showed that, after a mean time of 15.2 months 
from implantation, the repair tissue appeared as hyalinelike in 
twelve core biopsies, where rounded chondrocytes were observed 
JO UZQJDBM MBDVOBF XIJMF TJY XFSF DMBTTJ¾FE BTNJYFE UJTTVF BOE
GPVS TIPXFE B ¾CSPDBSUJMBHF BQQFBSBODF *OUFSFTUJOHMZ B IJHIFS
proportion of hyalinelike samples was found in the group of biopsies 
harvested after a minimum of 18 months from implantation than in 
those harvested at earlier times (83.3% and 43.8% respectively). 
Furthermore, none of the biopsies harvested after 18 months were 
DMBTTJ¾FEIJTUPMPHJDBMMZBT¾CSPDBSUJMBHF"MMUIFTQFDJNFOTTIPXFE
good integration of the engineered cartilage with the subchondral 
bone, independently of whether the tissue was hyalinelike, mixed or 
¾CSPDBSUJMBHJOPVT.PSFPWFSBDMFBSQSFTFODFPGBUJEFNBSLXIJDI
is typical of hyaline cartilage and is rarely seen in cartilage repair 
CJPQTJFTXBT PCTFSWFE JO UIPTF DBTFT IJTUPMPHJDBMMZ DMBTTJ¾FE BT
hyalinelike. Tissue regeneration was found even when implants were 
placed in joints that had already progressed to osteoarthrosis.5,14 
Graft failures The incidence of failed procedures, according to the 
1FUFSTPOEF¾OJUJPOXBT5IFWBTUNBKPSJUZPGHSBGU GBJMVSFT
(82%) occurred in salvage proceduresperformed in an attempt 
to delay arthroplasty in patients with osteoarthritis. No failures 
occurred conversely treated for pure traumatic lesions, nor in those 
cases of multiple lesions with condylar involvement where the defect 
on the condyle was not associated to a corresponding defect on the 
tibial plate, including defects on the patella. Given the small size was 
not possible to identify peculiar characteristics of this population. 
Nevertheless, failures seem to occur in patients with average age 
slightly higher then the rest of population (41.8 ± 10.2 years vs 37.1 ± 
12.3) and with higher incidence of “kissing lesions” (33.3 % vs 8.8% 
- p=0.0128). Therefore with this set of data, the presence of kissing 
MFTJPOTSFTVMUTUPCFUIFTJOHMFWBSJBCMFTJHOJ¾DBOUMZSFMBUFEUPHSBGU
failures (p<0.05, OR= 6.385). Logistic regression analysis was used 
to identify variables possibly associated with clinical outcome. We 
tested the same variables to also evaluate possible associations 
with treatment failures. The analyzed factors were the following: 
age, gender, body mass index, lesion size, lesion etiology, lesion 
type and location (isolated versus multiple defects), implantation 
technique (open or arthroscopy), failed prior cartilage resurfacing, 
presence of OA, concurrent meniscal/ ligament repair or osteotomy, 
follow-up period, pre-operative symptom duration. Subjective IKDC 
score, at univariate level, resulted positively related with follow-
up period (p=0.0368) and negatively with the patient degree of 
PTUFPBSUISJUJT	Q
UIJTMBUUFSDPODMVTJPOXBTBMTPDPO¾SNFE
CZNVMUJWBSJBUFBOBMZTJT	Q
/PPUIFSTJHOJ¾DBOUDPSSFMBUJPO
was observed at multivariate level. 
Several factors, including mechanical, biochemical and genetic ones, 
are involved in the etiopathogenesis of OA.15 Increased levels of 
catabolic enzymes, prostaglandins and nitric oxide (NO) have been 
observed in this pathology.16-17. Since the differentiated phenotype 
of chondrocytes grown in monolayers in vitro can be restored by 
TFFEJOHUIFDFMMTJOBUISFFEJNFOTJPOBMDPO¾HVSBUJPOUIVTBMMPXJOH
UIFDFMMTUPSFFYQSFTTUIFJSTQFDJ¾DHFOFTTPJUXPVMECFQPTTJCMF
to hypothesize a further use of this biomaterial in the treatment of 
early cartilage lesions also in OA patients. Chondrocytes grown in a 
UISFFEJNFOTJPOBMDPO¾HVSBUJPOSFBDRVJSFEUIFPSJHJOBMQIFOPUZQF
that was lost in the monolayer culture.4,18-21 This is an important 
DIBSBDUFSJTUJDPGUIFTFDFMMTBOEKVTUJ¾FTBVUPMPHPVTUSBOTQMBOUBUJPO
by the means of a biomaterial that allows both an easier surgical 
procedure and the implantation of differentiated and mature cells. 
The good clinical results and morphological characteristics of the 
OFXUJTTVFGVSUIFSTVQQPSUUIFMBCPSBUPSZ¾OEJOHT)PXFWFS
until now, the use of autologous chondrocyte transplantation, 
performed either by cells in suspension or carried by a biomaterial, 
is limited to the repair of cartilage damaged after traumatic lesions 
or in patients with osteochondritis dissecans.24 The data recently 
obtained25 demonstrate that chondrocytes grown onto a hyaluronic 
acid-based scaffold are able not only to re-differentiate and express 
their original phenotype, 4 but also reduce the production and 
expression of many factors involved in cartilage degradation. It is well 
known that NO is highly produced by chondrocytes from OA-derived 
chondrocytes and it is one of the molecules that triggers cartilage 
apoptosis and breakdown via activating matrix metalloproteinases 
activity. 26,27,28,29 Chondrocytes grown onto hyaluronic acid-
based scaffold are able to reduce the secretion of nitrites and the 
expression and secretion of MMP-13 and caspase, resulting in 
a lower percentage of apoptotic cells. It was demonstrated that 
hyaluronan protects chondrocytes from death receptor-induced 
apoptosis and this is mediated via the CD44 receptor.30 The cells 
TFFNUPCFOF¾UGSPNUIFQSFTFODFPGUIFIZBMVSPOBONPMFDVMFUIBU
operate on chondrocyte metabolism activating anabolic pathways. 
This is not really a surprise, since hyaluronan is a major constituent 
of the extracellular matrix of articular hyaline cartilage, and is 
highly abundant in the mesenchyme of the developing embryo.31 
As a ligand for the cell surface receptor CD44, hyaluronan promotes 
¾CSPCMBTUBEIFTJPOBOENJHSBUJPOBOENJOJNJ[FTJOIJCJUPSZDFMMDFMM
contacts by expanding the extracellular matrix facilitating the cell 
detachment and rounding requisites for mitosis, thereby promoting 
cell proliferation.32 It is possible to hypothesize that synthetic 
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matrices based on hyaluronic acid or derivatives of this molecules, 
such as Hyaff®, mimic the embryonic hyluronic acid-rich environment 
and when used as a delivery vehicle for cell-based therapies in adult 
organisms, promote a recapitulation of these embryonic events. 
This results in the activation of anabolic factors which induce the 
EJGGFSFOUJBUJPO PG UIF DFMMT XJUI UIF ¾OBM BJN PG GBDJMJUBUJOH UJTTVF
repair. The ability of the hyaluronan-based scaffold to reduce also 
the expression and production of molecules involved in cartilage 
degenerative diseases indicates its possible use to treat early lesions 
in osteoarthritic patients. But the problem have to be analyzed 
also from the clinical point of view. Few clinical studies present 
the results of autologous chondrocyte transplantation utilize in 
large degenerative osteoarthritis cartilage lesions.33,34 Although 
Minas33 reports 90% of patients satisfaction after treatment of 
large osteoarthritis lesions, the failure rate in this patient group in 
higher respect to focal lesions (17% and 10% respectively) and 55% 
of failures occurred in osteoarthritis group. Our experience in very 
similar: although we found high rate of clinical improvement, the 
outcome of patients affected by osteoarthritis is lower respect to 
the focal lesions and most of failures are concentrated in this group. 
5IFJNQPSUBOU¾OEJOHPGPVSTUVEZ JTUIBUUJTTVFSFHFOFSBUJPOXBT
found even when implants were placed in joints that had already 
QSPHSFTTFEUPPTUFPBSUISJUJT5IJT¾OEJOHTDPNCJOFEXJUISFTVMUTPG
in vitro studies can address us to suppose that low clinical success 
of tissue engineered cartilage implants can be connected mostly to 
mechanical problems. The clinical utilize of existing tissue engineered 
grafts in osteoarthritis still presents some unresolved problems. First, 
chondrocyte therapy is suitable for cartilage defects surrounded by 
healthy cartilage. In osteoarthritis, However, an entire compartment 
is damaged: the implant placed in the defect will be surrounded by 
damaged cartilage. The cytokines produced by the chondrocytes 
around the implant might cause dedifferentiation or apoptosis of the 
implanted cells. Also the absence of healthy cartilage shoulder can 
lead to the mechanical damage or mobilization of the implant. Some 
authors reports good clinical results of combination of autologous 
chondrocyte implantation with autologous osteochondral plugs.34 
Another important issue is represented by mechanical overloading 
of affected knee compartment even in early osteoarthritis. For this 
reason we cannot recommend the utilize of existing autologous 
chondrocyte implants for the treatment of osteoarthritis. For 
our opinion, the tissue engineered cartilage implant based on 
hyaluronic acid scaffold can be promising for the treatment of early 
osteoarthritis, but the mechanical properties of the graft and the 
mechanical e and biochemical environment of the joint have to be 
improved. Actually our group is involved in European Project STEPS 
which aims to solve this issues regarding the possibility to use tissue 
engineered cartilage in the osteoarthritis joint. 
10.2
Manipulation of endogenous healing beyond microfracture… 
D. Frisbie, United States of America 
In spite of the recent interest in assessing treatments for chondral 
defects, efforts have been underway for over 250 years to heal 
articular cartilage with only moderate progress. One must keep in 
mind that articular cartilage is a highly specialized tissue that needs 
an intact structure to perform its biochemical, biomechanical and 
physiological functions. Once the cartilage is damaged, the repair 
process is typically inadequate, leading to loss of joint integrity, 
more cartilage damage and more severe joint disease. Various 
therapies have attempted to improve resurfacing of cartilage defects 
including surgical modulation relying on endogenous cell repair 
(full-thickness curettage, spongialization, subchondral bone drilling, 
subchondral bone plate microfracture, and abrasion arthroplasty), 
grafting procedures (periosteal autografts, osteochondral graft, 
sternal cartilage autograft) and chondrocytes transplantation, 
relying on exogenous cell sources to promote healing.1 So far, no 
single treatment has clearly shown favorable results in all clinical 
situations long-term. However, arthroscopic subchondral bone 
plate microfracture (ASBPM) provides an economic, technically easy 
procedure that provides good repair tissue in many acute chondral 
defects without compromising the ability to subsequently perform 
other surgical techniques. 
Arthroscopic subchondral bone plate microfracture was developed, 
TUVEJFE BOE ¾STU VTFE DMJOJDBMMZ CZ + 3JDIBSE 4UFBENBO .% UP
enhance chondral resurfacing in human patients. In humans the 
procedure typically involves use of an arthroscopic shaver to do a 
rough shave that removes any cartilage remnants, hand-held curettes 
UPBTTVSFSFNPWBMPGUIFDBMDJ¾FEDBSUJMBHFMBZFSBOETVSHJDBMBXMT
to make numerous perforations through the subchondral bone 
plate. The procedure has been used in about 3,000 humans over 
the past 18 years. In a study2 evaluating human patients 7 to 17 
years after microfracture, 80% experienced a decrease in pain and 
JNQSPWFNFOUJOEBJMZMJWJOH4JHOJ¾DBOUJNQSPWFNFOUXBTSFDPSEFE
for the Lysholm function score and the Tegner activity scale. There 
XBTBMTPTJHOJ¾DBOUJNQSPWFNFOUJOUIF4'BOE80."$TDPSFT
These clinical successes have led to experimental work assessing 
the degree of improvement in placebo controlled studies. In 1996 a 
full thickness chondral defect model was developed on the medial 
condyle of horses to assess the improvement seen with ASBPM 
compared to non-ASBPM treated defects.3 The model was carried 
out in the horse to allow the use of routine arthroscopic equipment, 
access to cartilage with similar thickness to that of humans on 
the medial femoral condyle and the ability to subject the horse 
to controlled long-term strenuous exercise as well as this lesion 
being a clinical entity in the athletic horse. The goal of this study 
was to gain better understanding of how ASBPM may augment the 
healing processes using clinical, gross, histologic, and biochemical 
FYBNJOBUJPOT5IJTTUVEZEFNPOTUSBUFEUIBUBTJHOJ¾DBOUJODSFBTFJO
repair tissue was seen in defects treated with ASBPM compared to 
untreated defects and that there was an increase in type II collagen. 
It was surprising that the histologic character of the repair tissue 
was similar when both groups were compared. The character of the 
SFQBJSUJTTVFXBTBNJYUVSFNBJOMZPG¾CSPDBSUJMBHF5IFTFEBUBXFSF
BMTPMBUFSDPO¾SNFEJOFYQFSJNFOUBMNPEFMTJOEPHTBOESBCCJUTBT
well.4,5 The equine study also suggested that many of the events 
that led to differences between the ASBPM and non-ASBPM treated 
EFGFDUTPDDVSSFEQSJPSUPNPOUIT5IJT¾OEJOHMFEUPBGPMMPXVQ
study that evaluated the short-term effects of ASBPM treatment at 
the molecular level assessing tissues at 2 week intervals up to 8 
XFFLT5IJTTUVEZSFDPO¾SNFEBOVQSFHVMBUJPOPGUZQF**DPMMBHFO
with ASBPM when compared to non-ASBPM treated defects as well as 
the increased volume of tissue that histologically was not different. 
During model development it was observed that using a motorized 
shaver for debridement of partial thickness lesions may be retaining 
DBMDJ¾FE DBSUJMBHF -JLFXJTF BSFBTXJUI DBMDJ¾FE DBSUJMBHF SFUBJOFE
JO UIF ¾STU UXP FRVJOF TUVEJFT TVCKFDUJWFMZ IBE QPPS BUUBDINFOU
PG UIF SFQBJS UJTTVF UP TVSSPVOEJOH CPOF PS DBSUJMBHF 5P DPO¾SN
the consequences associated with incomplete debridement of the 
DBMDJ¾FEDBSUJMBHFBOPUIFSDPOUSPMMFETUVEZXBTVOEFSUBLFOXIJDI
TQFDJ¾DBMMZDPNQBSFEUIFQSFTFODFPSBCTFODFPGDBMDJ¾FEDBSUJMBHF
on defect healing with ASBPM, as well as, arthroscopic biopsy on 
long-term repair tissue healing.7 
The results of this study demonstrated a greater volume of repair 
UJTTVFXJUIUIFSFNPWBMPGDBMDJ¾FEDBSUJMBHF"TJHOJ¾DBOUOFHBUJWF
DPSSFMBUJPO UP QSFTFODF PG DBMDJ¾FE DBSUJMBHF BOE SFQBJS UJTTVF
attachment was also observed. No long-term adverse effects were 
noted with the arthroscopic biopsy of defects. Similar to other 
TUVEJFTOPTJHOJ¾DBOUEJGGFSFODFJOIJTUPMPHJDSFQBJSUJTTVFDIBSBDUFS
